Literature DB >> 24607029

A metric for evaluating the cardiac response to resynchronization therapy.

Yidi Ge1, Anne-Christine Huth Ruwald2, Valentina Kutyifa1, Scott McNitt1, Slava Polonsky1, Helmut Klein1, Ilan Goldenberg3, Scott D Solomon4, Elyse Foster5, Wojciech Zareba1, Arthur J Moss6.   

Abstract

We hypothesized that the response to cardiac resynchronization therapy with a defibrillator (CRT-D) in patients with mildly symptomatic heart failure (HF) is more favorable than the commonly referenced figure of 70%. This study involves the Multicenter Automatic Defibrillator Implantation Trial with Cardiac Resynchronization Therapy (MADIT-CRT) study population in which paired echocardiograms from baseline and 1-year follow-up were available in 621 implantable cardioverter-defibrillator-treated patients and 749 patients treated with CRT-D. We prespecified CRT-D responders as the patients who at 1-year follow-up had a reduction in left ventricular end-systolic volume (LVESV) that corresponded to the top (best) quintile of LVESV reduction in the implantable cardioverter-defibrillator-treated patients, that is, a ≥17% reduction in LVESV. Using this metric, 88% of patients treated with CRT-D and 91% of the patients treated with CRT-D with left bundle branch block (LBBB) were identified as cardiac resynchronization therapy responders. Landmark multivariate Cox model analyses revealed a significant interaction (p=0.038) involving LVESV (responders vs nonresponders) and LBBB (present vs not present) in risk reduction for HF or death. The interaction finding indicates that cardiac resynchronization therapy responders with LBBB have a significantly lower risk for HF or death (hazard ratio [HR] 0.24) than patients without LBBB (HR 0.62). In the patients treated with CRT-D, LVESV response was associated with reduction in the risk of death (HR 0.20, p<0.001). An increasing percent reduction in LVESV was associated with progressively lower rates of HF or death, a finding consistent with a dose-response relation. In conclusion, approximately 90% of CRT-D-treated patients in MADIT-CRT had a significant and meaningful reduction in LVESV, and these LVESV responders had reduced rates of cardiac events during long-term follow-up.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2014        PMID: 24607029     DOI: 10.1016/j.amjcard.2014.01.410

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  2 in total

1.  Postimplantation ventricular ectopic burden and clinical outcomes in cardiac resynchronization therapy-defibrillator patients: a MADIT-CRT substudy.

Authors:  Anne-Christine Ruwald; Mehmet K Aktas; Martin H Ruwald; Valentina Kutyifa; Scott McNitt; Christian Jons; Suneet Mittal; Jonathan S Steinberg; James P Daubert; Arthur J Moss; Wojciech Zareba
Journal:  Ann Noninvasive Electrocardiol       Date:  2017-09-20       Impact factor: 1.468

2.  Prediction of clinical outcome in patients treated with cardiac resynchronization therapy - the role of NT-ProBNP and a combined response score.

Authors:  Z Bakos; N C Chatterjee; C Reitan; J P Singh; R Borgquist
Journal:  BMC Cardiovasc Disord       Date:  2018-04-24       Impact factor: 2.298

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.